Tag: research

KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING

SYDNEY, Dec. 15, 2022 /PRNewswire/ — Kazia Therapeutics Minimal (NASDAQ: KZIA ASX: KZA), an oncology-targeted drug growth business, is pleased to announce a collaboration with QIMR Berghofer Healthcare Exploration Institute, a single of Australia’s foremost most cancers study centres, to discover novel works by using of paxalisib in solid tumours.

The exploration project is led by Professor Sudha Rao, a major specialist in transcriptional biology, particularly as it applies to the perform of the immune procedure in most cancers. Professor Rao’s laboratory works closely with pharmaceutical organizations and with clinicians to take a look at progressive strategies to most cancers treatment method.

The collaboration is ongoing and will create on initial research that has previously led to the filing of a patent, like the use of paxalisib as an immune modulator in the treatment of conditions these types of as breast most cancers.

Critical Details

  • Paxalisib is a member of a course of medication recognized as PI3K inhibitors. The direct anti-cancer consequences of PI3K inhibitors are effectively shown, and 5 therapies have been accepted by the US Food and drug administration to day.
  • Professor Rao’s investigation identifies an completely different impact of PI3K inhibition: as a modulator of the immune microenvironment within just and all around the tumour. Administration of PI3K inhibitors these kinds of as paxalisib, at doses and frequencies distinctive to those conventionally utilized, appears to activate the immune program in the tumour, building it a lot more susceptive to immunotherapy.
  • The exploration opens up an essential chance for paxalisib in blend with medication these types of as Keytruda® (pembrolizumab, Merck) and Opdivo® (nivolumab, Bristol Myers Squibb) for the treatment of ailments this sort of as breast cancer and lung cancer. If demonstrated powerful in scientific trials, such combos may possibly have the likely to enhance outcomes for individuals.
  • It is expected that the effects of the study will be posted in 1H CY2023, and conversations are ongoing pertaining to potential translation to clinical trials in CY2023.

“These are incredibly promising information,” commented Professor Rao, Principal Investigator on the venture. “In remedy-resistant pre-clinical designs of breast cancer, paxalisib has shown encouraging final results in inhibiting each the major tumour load and metastasis by reinvigorating the immune program within just the tumour microenvironment. We look forward to continuing our research, and with any luck , viewing this do the job direct to a scientific demo in because of program.”

“Professor Rao’s crew are doing work at the primary edge of cancer study, and we are enormously grateful for their do the job on paxalisib,” reported Dr James Garner, CEO of Kazia. “An essential element of our new system for the drug has been to increase its field of prospect outdoors of cancers of the brain. This do the job, which has largely targeted on breast most cancers, but which has applicability to other strong tumours, builds on some promising details we earlier shared which shown the likely of paxalisib in melanoma. We appear ahead to doing work with the QIMR Berghofer team to just take this investigation to the upcoming phase.”

For A lot more Data, Please Call:-

Jane Lowe
IR Department
[email protected]
Telephone: +61 411 117 774

About Kazia Therapeutics Minimal

Kazia Therapeutics Restricted (NASDAQ: KZIA ASX: KZA) is an oncology-concentrated drug development company, based in Sydney, Australia.

Our guide software is paxalisib, a mind-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is staying formulated to address a number of sorts of mind cancer. Certified from Genentech in late 2016, paxalisib is or has been the issue of 10 scientific trials in this disease. A accomplished phase II examine in glioblastoma reported promising signals of efficacy in 2021, and a pivotal review for registration, GBM AGILE, is ongoing, with remaining information expected in CY2023. Other medical trials are ongoing in brain metastases, diffuse midline gliomas, and key CNS lymphoma, with many of these owning noted encouraging interim info.

Paxalisib was granted Orphan Drug Designation for glioblastoma by the US Food and drug administration in February 2018, and Speedy Track Designation for glioblastoma by the US Food and drug administration in August 2020. In addition, paxalisib was granted Unusual Pediatric Sickness Designation and Orphan Designation by the US Food and drug administration for DIPG in August 2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July 2022, respectively.

Kazia is also creating EVT801, a small-molecule inhibitor of VEGFR3, which was certified from Evotec SE in April 2021. Preclinical information has revealed EVT801 to be active towards a broad selection of tumour forms and has furnished persuasive evidence of synergy with immuno-oncology agents. A stage I research commenced recruitment in November 2021.

For additional data, make sure you stop by www.kaziatherapeutics.com or follow us on Twitter @KaziaTx.

Forward-Looking Statements

This announcement might comprise forward-seeking statements, which can frequently be determined as these types of by the use of text such as “could,” “will,” “estimate,” “foreseeable future,” “ahead,” “foresee,” or other related words and phrases. Any statement describing Kazia’s upcoming ideas, procedures, intentions, anticipations, goals, ambitions or potential customers, and other statements that are not historical facts, are also forward-looking statements, together with, but not constrained to, statements regarding: the timing for effects and facts associated to Kazia’s clinical and preclinical trials, and Kazia’s strategy and ideas with respect to its packages, such as paxalisib and EVT801. This kind of statements are centered on Kazia’s expectations and projections about future situations and long term trends impacting its business and are subject matter to sure threats and uncertainties that could trigger precise effects to vary materially from all those predicted in the forward-on the lookout statements, including risks and uncertainties: linked with medical and preclinical trials and product or service growth, connected to regulatory approvals, and the similar to the impression of international economic circumstances. These and other threats and uncertainties are explained extra totally in Kazia’s Once-a-year Report, submitted on form 20-F with the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking assertion, irrespective of whether as a end result of new data, potential gatherings, or usually, besides as necessary under applicable law. You ought to not location undue reliance on these forward-on the lookout statements, which utilize only as of the date of this announcement.

Resource Kazia Therapeutics Limited

Medical student research opportunities with Leelabati Biswas | AMA Update Video

AMA Update addresses a assortment of health treatment subjects influencing the life of medical professionals, inhabitants, healthcare students and sufferers. From private practice and wellbeing method leaders to researchers and public wellness officers, listen to from the authorities in medicine on COVID-19, monkeypox, health-related instruction, advocacy concerns, burnout, vaccines and much more.


 

Showcased topic and speakers

In today’s AMA Update, Leela Biswas, an MD/PhD applicant at Rutgers Robert Wood Johnson Health care College, is this year’s AMA Study Challenge winner, which will come with a $10,000 grand prize sponsored by Laurel Road. She discusses professional medical pupil research grants and funding, ideas for finding a mentor, and additional about her winning investigate: “Decoding Being pregnant Loss, Validating a Novel Genetic Biomarker of Inadequate Egg High quality.” AMA Chief Practical experience Officer Todd Unger hosts.

View 2022 AMA Investigate Obstacle finals.

Browse Leela’s “Validating a genetic biomarker tied to miscarriages” investigation submission.

Speaker

  • Leela Biswas, an MD/PhD applicant, Rutgers Robert Wood Johnson Medical School

Unger: Hi there and welcome to the AMA Update video and podcast. Currently, we are joined by Leela Biswas, an MD/PhD candidate at Rutgers Robert Wood Johnson Healthcare University, in New Brunswick, New Jersey, and also, this year’s winner of the AMA Research Challenge function, which I had the satisfaction of hosting, just a couple of days ago. We’re heading to talk to her about her study journey and what it feels like to be a winner of the $10,000 grand prize. I am Todd Unger, AMA’s main knowledge officer, in Chicago. Leela, welcome.

Biswas: Hi, Todd. How are you? Great to see you.

Unger: I’m wonderful. I bet you are emotion rather superior. It was type of a fantastic week for you. Huh?

Biswas: Yes, an fantastic 7 days, really thrilling.

Unger: Perfectly, congrats once again on winning the $10,000 grand prize for the AMA Analysis Challenge. That’s furnished by our friends at Laurel Street. Thank you, Laurel Highway. Just before we dive in, I thought it’d be pleasurable just to observe that second you won. How does it truly feel to be the winner of the 2022 AMA Exploration Problem with a grand prize of $10,000?

Biswas: I’m stunned. Oh my goodness, my heart is beating genuinely swiftly. Wow. I’m incredibly shocked. I was anticipating a whole lot of concerns and I was psyched for a adhere to-up discussion on the exploration, but this is genuinely fantastic news.

I am incredibly flattered, simply because the study from my colleagues, in both equally the semi-finals and the finals, was remarkable. I was in just an incomparable team of enjoyable clinicians and student researchers. So I experience quite fortunate to be selected as the winner. I’m incredibly flattered. Thank you so substantially.

Unger: That was truly exciting. That was a great reaction. As you know, successful the AMA Research Obstacle, it is really a major accomplishment.

There had been 1,200 entries for the party, which is a report. And then you were picked by an elite panel of judges—Dr. Kirsten Bibbins-Domingo, Dr. Sanjay Desai and Dr. Clyde Yancy—to acquire this year’s Investigate Problem. Did you imagine you were going to occur out on top of that?

Biswas: Very well, it was an amazing area of rivals, from the semifinalists all the way down to 5 incredible finalists, ranging in exploration from resuscitation devices to AI detection of pancreatic most cancers. It was totally spectacular. So I was amazed to be chosen, just simply because the subject was so stunning. If you have not watched it, check it out. It truly is incredible.

Unger: Now, you claimed, you’ve received an additional extensive volume of faculty and training. It sounded about 40 years that this cash is heading to arrive in helpful. Is that correct?

Biswas: Yeah. Yeah. So it really is an 8-yr system. So so lots of expenses related with that, and I know Laurel Highway is really familiar with that working experience for a whole lot of college students. And so this will be definitely beneficial in aiding to go that together and so I can become a health practitioner scientist. Get to residency, get to fellowship and then make it around the last hump. And hopefully, have a faculty situation and do some a lot more meaningful investigate that improvements affected individual care.

Unger: Nicely, just one detail you stated was, the explanation you entered the obstacle was to get diverse perspectives and feed-back that seriously crossed specialty. This is a multi-specialty party, of class. Notify us extra about that and why it was this sort of an significant motivator for you and piece of study in basic.

Biswas: Yeah. Medication is an interdisciplinary occupation by its pretty character. Just about every human being is designed up of so a lot of distinct organ methods, as we know from just the preclinical curriculum, and all of people keep on to interact for the rest of a person’s life. And as we go along, the medical treatment group is led by medical professionals from many, several, several different disciplines, and it can be crucial that we can all communicate to each and every other.

And the field that I’m in, it can be surely fertility and obstetrics, but it can be also precision medicine, and precision drugs crosses each individual self-control. So it was really important for me to see how other medical professionals and other fields thought about my investigation.

The way they think about their scientific complications is unique from the way a different health practitioner may and so those people views definitely enhance the type of research that we’re undertaking. The much more physicians can discuss to just about every other, willpower to discipline, the greater patient care is and the a lot more that we can do for people.

Unger: Now, just about every good piece of investigation begins with a genuinely good, exciting, crucial query. What had been you seeking to solve with this?

Biswas: Yeah. So ideal now, the only biomarker that we have for a woman’s egg top quality, how good her eggs are in terms of chromosomal abnormality, is maternal age. But there are clients who have weak high quality eggs at the exceptional age window. So right now, sufferers assume, late 20s, early 30s, great time to get expecting.

And for most folks, it is, but there are men and women who will not healthy that paradigm. And they consider to get pregnant for a calendar year, then they stop up in the IVF clinic. They go as a result of an IVF cycle and they discover out that, even while on paper clinically they look fantastic, their age is excellent, that 80{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f}, 100{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} of their embryos are chromosomally irregular and that is devastating. It is really so costly. It really is emotionally taxing.

And so we want to adjust that paradigm. We want to acquire a large action again, before people are striving to get pregnant and say, can we establish persons who are not going to do properly in advance? And then that data will make it possible for clinicians and doctors and the people to work jointly to style and design a care prepare that actually optimizes pregnancy results from the get go, relatively than hoping and failing and not understanding what’s heading on. We are empowering sufferers and medical professionals to make much more personalised selections.

Unger: Leela, the way that you just explained it is genuinely compelling, since I am certain that waiting around time, when somebody’s figuring out, this is not heading as planned, that is truly distressing. So what you might be stating is really meaningful and the science is what the judges truly circled in on. We reported it was pretty compelling. What was exclusive about your strategy in executing this function?

Biswas: It is devastating. You’re thoroughly appropriate, Todd, and that is why we had been psyched about this issue. We wanted to make modifications for people. And in conditions of the science, there were being a few of matters that have been truly unique about the way that we did this.

So this is an NIH-funded project, led by my PI, Karen Schindler, and our collaborator, Dr. Jinchuan Xing and they took a few of definitely exciting techniques in terms of planning the experiment. So 1 is we are concentrating on people who are clinically standard, clinically glance good, but have this puzzle of a dilemma. So like I reported, they’re coming into clinic and they appear to be entirely standard, but then items are not operating out soon after seeking for being pregnant.

And so by using a population that we you should not ordinarily assume of as owning a ailment in the very first location, we’re capable to essentially appear at men and women in a a lot more customized way and so that was genuinely special in this article. We’re truly digging into what would make me, me and what helps make you, you and how that influences our health care in standard and our health in the course of our lifespan.

And then a further thing was the experimental style. So right here, we took genomic or genetic data from people and then we introduced that into the laboratory. And we have been ready to do an successful screening using cells in a dish, but then we all know that cells in a dish usually are not people and they are not even full organisms.

So we ended up able to do that successful screening and tests of variants and cells in a dish and then deliver that again and exam it rigorously making use of a entire organism, so a full mouse design, which is the additional pricey piece.

So we were being in a position to do actually strong science, although being really efficient and smart about it. And I imagine that was sophisticated about the research and which is what the judges appreciated. And finally, it helps make it extra translational and much more capable to be rapidly translated into the clinic, and that’s what we are enthusiastic about.

Unger: What do you think would be the extended-expression influence here, if you could establish a marker like this? How is that going to modify matters going forward?

Biswas: Yeah. So what I imagine is that we will be equipped to determine and validate variants like this lengthy phrase.

I assume this is an identifiable genetic basis of a authentic phenotype and in the clinic, my hope that is when we’re equipped to absolutely translate all of this to the clinic, whether or not it’s this variant or other variants, that people effectively ahead of they are interested in conceiving would arrive in and get a genetic check, which is just a blood check, that would give medical professionals and sufferers perception into how a patient’s eggs are probably to carry out very long phrase. So it’s not just maternal age.

Maternal age is critical, but bringing in that genetic piece from the beginning, so that persons can program their reproductive upcoming. It is about empowering patients, empowering physicians with all of the information, so that they can make selections that in fact enhance the pregnancy outcomes from the get go. So early genetic testing, relatively than seeking and failing and then being devastated.

Unger: Now, it seems like you had great guidance from some wonderful mentors. What is your suggestions to other health-related learners out there who they really don’t know where by to commence? How do you get connected with mentors in this to support jumpstart your analysis profession?

Biswas: Yeah. It can be actually challenging and daunting, when you are in faculty and you want to get into investigation, and you just never know exactly where to start. So I believe a couple of things are at perform. So a single issue is be open to alternatives. Occasionally, you can get email messages or see a information report about a PI that’s seriously exciting to you.

Never be frightened to cold-e mail individuals and arrive at out. Deliver them your resume. Inform them why you might be fascinated and say, “Hey, I never have a great deal of experience, but I am enthusiastic to find out and keen to bounce into the lab or into your scientific study project. Is there any way that I could aid out?”

I assume just using options and then also becoming open to serendipity. So I have my excellent, astounding PI in the laboratory and she is my crucial study mentor, Dr. Karen Schindler. But then I also have other mentors that I have gained as a result of just likely by means of health-related faculty and becoming open up.

So, for illustration, I lately did a study course in Woods Gap, up in Massachusetts, at the storied maritime organic laboratories, which is amazing. And there, I got to fulfill yet another clinician scientist mentor, Dr. Elizabeth Taglauer, who’s been mentoring me in conditions of vocation planning and becoming a medical professional-scientist and moving by this process.

And so you have to be open up to all the diverse chances that are out there. Get options when they appear and just be enthusiastic. Be energized and when you get knocked down, received to stand again up and preserve attempting.

Unger: Very well, Leela, of course, analysis will not change out the way you assume it will all the time, and that get again up, dust on your own off and keep testing, that is actually crucial. Clearly, loads of issues in starting up a occupation as a medical doctor-scientist and the Research Obstacle is the way that AMA is really making an attempt to assistance individuals out there get that vocation commenced. Is there any other way that the AMA can enable learners like you get their analysis careers going?

Biswas: Yeah, completely. The AMA is nationally, and perhaps internationally, identified as the most strong health practitioner advocacy group in the nation. And in phrases of the advocacy, they can do for raising residency slots, so that we can produce a lot more medical professionals.

The additional medical professionals that we have in basic, the additional health practitioner-scientists we can have as perfectly. Every single physician has inquiries that they identify in the clinic, has curiosity and can do some form of study in some way, no matter whether it is simple investigation, translational study, medical study, smaller, huge, it will not make a difference. Just about every medical doctor is poised to go science and medication ahead for the betterment of clients.

In addition, advocating for more NIH funding. So funding from the Nationwide Institutes of Wellness is essential for performing clinical investigation. These forms of research are really costly, and we need to invest in both of those standard and medical study to maintain going drugs forward.

I feel individuals are definitely important, and then as a student, I imagine becoming a member of the AMA, connecting with other physicians, getting some of that professional growth abilities and doing things like the Research Challenge. Using options to develop your investigate, learn how to existing, attain suggestions other folks, other disciplines, so crucial, so impactful. So all those are points that the AMA is doing and can do in the long term as nicely.

Unger: Well, I hope we performed a portion in launching your clearly interesting vocation as a medical doctor-scientist. I just want to say congratulations yet again on your achievements and thank you once more to Laurel Road for sponsoring the $10,000 grand prize for a second year in a row.

I would just like to inspire every person out there, all you professional medical pupils, inhabitants, intercontinental healthcare graduates, interested and jumpstarting your investigate vocation, do what Leela did and make sure that you submit your investigate proposal for up coming year’s Exploration Challenge.

Also, if you want to see how it is really carried out perfectly, choose a glance at the Research Challenge, which is up in complete on AMA’s YouTube channel. You can see all of the displays, all the judging and see accurately how it goes. And everybody, thanks for signing up for us today. You can obtain all our films at ama-assn.org/podcasts. Many thanks for becoming a member of us currently and be sure to, acquire care.

Biswas: Thank you, Todd, and thank you to Laurel Highway and all of the viewers.

Disclaimer: The viewpoints expressed in this movie are people of the members and/or do not automatically mirror the sights and policies of the AMA.

Building Equity in Biomedical Research

“We have to create these opportunities,” Reede said. “The Visiting Research Internship Program provides the opportunities for these students to start to ask: Is there a place for me in this?”

Harvard Catalyst, the university’s clinical and translational science center, coordinates the VRIP in partnership with the HMS Office for Diversity Inclusion and Community Partnership and with funding from the National Center for Advancing Translational Sciences (NCATS), a program of the National Institutes of Health.

NCATS places a strong emphasis on integrating diversity and inclusion throughout its national programs. Along with an annual faculty fellowship, VRIP is a core program.

Opening doors, enlightening the path

For Gerald Lilly, now a physician, a VRIP summer in 2015 provided an opportunity to work on CRISPR gene editing and the experience sparked a love of science that Lilly is still chasing.

A Black man from the Midwest, Lilly was a second-year med student interested in exploring a research career when he was accepted into the program to collaborate with oncologist Daniel Bauer, HMS associate professor of pediatrics and the Donald S. Frederickson, MD Associate Professor of Pediatrics at Boston Children’s Hospital, who was doing work in cancer genetics.

Today, Lilly stands out in an elite group of Americans who’ve been named Presidential Management Fellows by a federal leadership-development program started by President Jimmy Carter in the 1970s.

The role places Lilly at the heart of pandemic preparedness, working on vaccine quality control at the National Institute of Allergy and Infectious Diseases (NIAID).

VRIP “enlightened my path,” Lilly said in an interview.

“It helped me to understand that I really wanted to do science with my MD and get more experience in the lab. I didn’t see direct patient care as my primary role, and that’s not what I’m doing in my career. I want to affect people by helping advance the science.”

Another former VRIP participant, Ross O’Hagan from the 2019 cohort, said the program convinced him to dig deeper into a career in translational science.

A student at the Icahn School of Medicine at Mount Sinai, he went on to earn a spot in the NIH Medical Research Scholars program and became immersed in pioneering translational work in the NIH lab of Lasker Clinical Research Scholar Nehal Mehta.

VRIP “made me like research so much that I wanted to train for a whole extra year,” O’Hagan said, laughing.

Living the academic life

VRIP targets first- and second-year medical students who are at critical junctures in their careers and links them with an HMS-affiliated clinician-scientist as research mentor.

Working on-site in Boston for two months, students are immersed in real-world academic research along with an intensive curriculum of seminars that cover research methods and practices.

Internationally recognized cancer researcher Marsha Moses, the HMS Julia Dyckman Andrus Professor of Surgery, whose lab is at Boston Children’s, was a first-time VRIP mentor in 2002, hosting Michael Dang, a medical student from the Texas Tech University Health Sciences Center.

As a result, Dang learned to work with cell cultures in a state-of-the-art wet-bench laboratory under the immediate tutelage of Roopali Roy, an HMS instructor in surgery in Moses’ lab at Boston Children’s.

In addition to working on his research project and immersing himself in the Harvard Catalyst curriculum, Dang attended weekly lab meetings and journal clubs. He was one of eight VRIP awardees in the 2022 session working in labs across the HMS campus this past summer.

“It’s important for young folks to understand what it means to do science for a living,” Moses said.

“To spend time working at the bench with really smart, dedicated, inspired young women and men who at the end of the day are not very different than they are, is invaluable,” she said.

That’s especially true, Moses said, for members of groups historically underrepresented in medicine, and for young women, who may not have had access to the same pool of mentors as more privileged students have.

Mentors who ‘get it’

Gezzer Ortega, an HMS instructor in surgery at Brigham and Women’s Hospital, knows what it’s like to work your way into an academic research career without a road map or mentors to guide you.

As the eldest son of Dominican immigrants who spoke only Spanish, and the first in his family to go to college, he figured out mostly for himself how to get into and navigate college, medical school, and then graduate school for his master of public health program.  When Ortega sees students who come from similar circumstances, he gets it.

Ortega saw aspects of his own path in Bryan Torres, a second-year medical student at Tulane University who grew up in an impoverished Hispanic community with immigrant, non-English speaking parents. Ortega jumped at the opportunity to help bring a fellow Latino into clinical science.

Torres said knowing he was going to be matched with a mentor who comes from a similar background was a “huge motivation” in applying for a VRIP spot.

“As a minority in medicine, it’s sometimes very lonely. It was really hard to find mentors. When I did find them — all of whom were amazing — rarely, if ever, did they look like me,” Torres said.

VRIP 2022 graduate Lacey Foster, a Black woman in her second year at the Keck School of Medicine of USC, echoed that experience, and said it illustrates the need for greater diversity in science and medicine.

“Everyone brings their lived experiences to everything that they do. Having people from different backgrounds and ethnicities bring their perspectives is really instrumental, especially in research, where we’re aiming to answer questions in innovative ways,” she said.

“In medicine, we see a diverse group of patients and I think it is important for our physician population to reflect the diversity in our patients.”

Foster recently started a nonprofit, the Foster Family Foundation, to provide mentorship, guidance, and financial support to students from historically Black colleges and universities who want to go to medical school.

Inclusive mentoring

For underrepresented groups in particular, “mentorship helps open pathways that would otherwise not be available to them,” said Meena Nathan, HMS assistant professor of surgery at Boston Children’s, who has mentored VRIP participants for the past five years.

“Having a diverse population of caregivers improves health care for underrepresented populations,” she said.

This year Mischael Saint-Sume, a Black second-year medical student at Morehouse School of Medicine, got a taste of life in Nathan’s pediatric cardiac surgery research lab, sleuthing out the incidence of a serious surgical complication — vocal cord paralysis — in order to understand how to prevent it.

For Nathan, the most rewarding part of participating in the program is being able to help young students like Saint-Sume realize what they want to do.

“I was mentored as a student, as a resident, and as junior faculty, so part of it is giving back,” she said. “You need to help the next generations the same way you were helped when you were starting out.”

That mentor-mentee relationship is built into the DNA of science, said Reede.

“It’s how all of us got to where we are. It’s something that’s always happened in science, but not everybody was included. VRIP is saying, ‘Let’s open this up so more can be a part of this journey.’”

NIH’s All of Us Research Program returns genetic health-related results to participants

News Release

Tuesday, December 13, 2022


Landmark precision medicine effort returns value to research participants by sharing tailored, actionable health-related reports.

The National Institutes of Health’s All of Us Research Program has begun returning personalized health-related DNA results to more than 155,000 participants, with reports detailing whether participants have an increased risk for specific health conditions and how their body might process certain medications. This marks a major milestone for the program, delivering on its promise to share information and return value to participants.

“Knowledge is powerful. By returning health-related DNA information to participants, we are changing the research paradigm, turning it into a two-way street – fueling both scientific and personal discovery that could help individuals navigate their own health,” said Josh Denny, M.D., M.S., chief executive officer of the All of Us Research Program. “This type of partnership with our participants is crucial for building trust and fulfilling the commitment we made to drive research that can offer meaningful insights for all.”

All of Us aims to partner with at least 1 million people who reflect the diversity of the United States to accelerate medical breakthroughs. About 80{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} of All of Us participants represent communities that have been historically underrepresented in medical research, and nearly 50{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} of All of Us participants identify with a racial or ethnic minority group. The program started returning genetic ancestry and trait results to participants in December 2020. So far, the program has offered genetic ancestry and traits results to more than 175,000 participants and continues to return about 6,000 results each month.

In this first phase of returning health-related DNA results, participants who provided a blood sample and consented to receive genomic information are being individually invited to receive their results. They can choose which health-related results they want, if any. Those who choose to receive results will get an alert several weeks later when their results are ready. Additionally, genetic counselors are available to meet with participants and their family members or health care provider to discuss and interpret their results.

The program’s Hereditary Disease Risk report, informed by recommendations from the American College of Medical Genetics and Genomics, includes 59 genes and variants that are associated with serious, medically-actionable health conditions. These genes are linked with an increased risk of specific cancers, heart conditions, blood disorders, and more. The program anticipates that 2-3{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} of participants will receive a result showing a pathogenic or likely pathogenic variant linked in one of the genes included in the report. Those whose results show they may have an increased risk of a serious health condition will be offered a clinical DNA test through the program’s genetic counseling resource, conducted outside of the program at no cost. This clinical DNA test will be conducted by Color Health, which provides genetic counseling services to All of Us participants.

Participants can also choose to receive a Medicine and Your DNA report that includes seven genes that are known to affect how the body processes certain medicines. Nearly all participants will learn more about how their bodies process medicines based on these results, however, participants are advised to consult a health care provider and undergo the appropriate clinical testing prior to considering changes to medications.

“Our participants care about their health as well as medical research. We strive to share information with them in a responsible, accessible, and impactful way that honors their trust in us and provides them with tools to continue to learn more about their own health,” said Karriem Watson, D.H.Sc., M.S., M.P.H., “This intentional focus brings us one step closer to advancing health equity for our participants and can serve as a catalyst for change to increase representation in medical research.”

“Returning information in research programs is the ethical choice, but must be done responsibly and equitably,” said Alicia Zhou, Ph.D., chief science officer of Color Health, the Genetic Counseling Resource for the All of Us Research Program. “All of Us is setting a new precedent for longitudinal research programs.”

All of Us works with a consortium of national and community partners across the United States to help reach people and collect DNA samples and data from surveys, physical measurements, electronic health records (EHRs), and wearable devices. The program’s Data and Research Center, Participant Technology Systems Center, and Genetic Counseling Resource worked closely with the program and other partners to develop the process for returning health-related genetic results. The program’s Biobank and Genome Centers collaborated to generate the genomic data that informs the personalized results.

The program plans to increase the number of participants who are invited to receive genetic health-related results throughout 2023, including new participants who join the program.

All of Us is a registered service mark of the U.S. Department of Health & Human Services (HHS).

About the All of Us Research Program: The mission of the All of Us Research Program is to accelerate health research and medical breakthroughs, enabling individualized prevention, treatment, and care for all of us. The program will partner with at least 1 million people who reflect the diversity of the United States to build one of the largest, most diverse biomedical data resources of its kind. Data is made available to researchers to drive scientific discoveries into the biological, environmental, and behavioral factors that influence health and disease. For more information, visit www.ResearchAllofUs.org, www.JoinAllofUs.org, and https://www.AllofUs.nih.gov/.

About the National Institutes of Health (NIH):
NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health®

###

NJ warehouse keeps brain, blood and stem cells ready for medical research

Keith and Jenny DiMarino have been expecting their 3rd kid 11 years in the past when they received e-mails that promoted the preservation of stem cells from their baby’s umbilical twine.

The pair opted not to do so, but the principle fascinated Keith DiMarino, who was then growing the South Jersey document storage organization he recognized in 2003. He went on to extend and relocate his DocuVault facility many situations, and in 2021, he released GenVault, an ultracold biorepository able of preserving 60 million frozen samples of blood plasma and serum, brain and other human or animal tissues, and vaccines.

Cell lines — similar copies developed by culturing a one cell — also are stored at GenVault and can quantity in the thousands and thousands. They’re raw elements of exploration into avoidance and treatment method of illnesses these kinds of as most cancers, Alzheimer’s, habit, and COVID-19 at the mobile and genetic amount.

“We’re not a laboratory. We’re a storage facility, and the lifestyle sciences increase is driving a need for much more storage facilities,” DiMarino stated as he led a tour of the five-story, 500,000-sq.-foot DocuVault and GenVault intricate in West Deptford, Gloucester County. He is the president and main executive officer of the corporation, which has 100 staff members.

Institutional, tutorial, and commercial enterprises nationwide, such as people in significant lifetime sciences hubs these kinds of as Philadelphia, are included in these types of investigation and create options for personal firms this kind of as GenVault.

“There are other biorepositories,” reported DiMarino, 45, who lives in Wayne with his spouse, a previous educator, and their four kids. “But I never imagine there’s another biorepository like this.”

DiMarino cited his custom-made vertical storage design and style, abundantly redundant fire suppression, electricity, and protection systems, and GenVault’s much more than 25-car or truck transportation fleet. Transportation cars incorporate refrigerated tractor-trailers equipped to transport an complete laboratory’s value of materials across the nation.

Government director Emily Younger likened GenVault to a “biological library” that picks up and delivers.

“We’re an archive of components used by tutorial as perfectly as pharmaceutical scientists,” she said. “We can retrieve their sample within just 6 minutes and get it out the door to them in two hours. We can do swift retrieval because we know specifically where by every little thing is.”

Though North and Central New Jersey are identified for their focus of corporate pharmaceutical production facilities, South Jersey has not been widely regarded — even in just the Philly area — as an emerging daily life sciences cluster.

Nonetheless, Camden has been house to the Coriell Institute for Medical Investigation considering that 1953. In new several years the town also has seen the opening of the Cooper Healthcare College of Rowan University as nicely as the Joint Heart for Overall health Sciences, a collaboration amid Rowan, Cooper, Rutgers College-Camden, and Camden County College. And last month, Rowan University and Virtua Health announced strategies for the Virtua Health and fitness University of Medicine & Life Sciences, a new facility that will include a research ingredient.

» Read through Much more: Rowan College and Virtua Well being unveil designs for new college of drugs and health and fitness

“The foreseeable future is really promising,” claimed Jean-Pierre Issa, president and CEO of Coriell. The nonprofit is in the early stages of setting up a key enlargement in Camden, which include a new headquarters.

Issa said Coriell also is partnering with Cooper and Rowan to build a cancer analysis facility in South Jersey substantial enough to be regarded and designated a most cancers heart by the National Cancer Institute. And he welcomed the presence of a non-public organization like GenVault to serve the demands of researchers in the course of the Philly location and bolster the existence sciences help infrastructure in South Jersey.

Dan Keashen, spokesman for the Rowan College-Rutgers Camden Joint Board of Governors — which oversees the Joint Centre for Wellness Sciences — claimed the enlargement of facilities and advancement of partnerships make the metropolis “ripe for new investments” in the lifetime sciences.

“The biosciences and their progress are vital to the eds and meds corridor in the town that is [collectively] the major employer in the tri-county region,” he mentioned.

Issa reported additional life sciences development would depend on far more condition aid centered on building incubator place and amenities offered for standard science investigation.

“There’s a huge option for South Jersey, but in buy to get gain of this you require a essential mass of infrastructure and science in the area,” he stated. “We want to do every thing that Philadelphia has accomplished.”

DiMarino commenced DocuVault in 2003 just after leasing a 3,000-square-foot former foods warehouse in Woodbury, in which he grew up.

“It continue to smelled like barbecue sauce, but the hire was good and it was in my hometown,” he reported.

He claimed his father, Anthony J. DiMarino Jr., the director of the Digestive Health Institute at Thomas Jefferson University, was an early trader in the fledgling doc storage small business.

The organization swiftly outgrew the Woodbury warehouse, moved to and outgrew a rented room in Woodbury Heights, and relocated to two other Gloucester County places just before DiMarino intended and purpose-built a new facility for DocuVault on Imperial Drive in West Deptford in 2016.

There was plenty of ground on the 10½-acre internet site to enable for design of the biorepository that was using shape in his imagination, mentioned DiMarino, whose father informed him how preserved serum from the blood of American military services recruits in the late 1940s get rid of mild on the prevalence of celiac disease.

“I could not believe it at initially,” DiMarino said. “It’s so impressive to understand we are capable to check blood from the 1940s, and how valuable and significant [preserved] blood can be.”

Design commenced in 2019 the whole sophisticated expense additional than $25 million to make. Younger was a career applicant when she initially noticed the function-in-progress in 2019 and listened to DiMarino describe how he planned to make it operable.

“I couldn’t think my eyes,” she reported. “Such an expansive place but used so effectively. Keith is a visionary chief.”

DiMarino also credits his father with “teaching me to genuinely take care” of his clients. He worked with Young — who has 20 years of industrial laboratory practical experience — to provide for distant visible inspection and other systems to reassure researchers that GenVault is getting appropriate care of their mobile traces and other crucial components concerned in what might be their life’s get the job done.

“We will spot a digital camera straight in front of their inventory, and they can have a personal viewing session any time,” DiMarino claimed. “They just want to know it is there.”

Young explained a superior number of purchasers are dividing their samples among two or far more destinations, just in case. Other people entrust not only their samples with GenVault but retail store prepared products involving their research at DocuVault.

“There are a great deal of [storage] synergies,” she mentioned. “Researchers also create lab publications, endnotes, files and other paperwork.”

Offered that a cell line could be applied to supply treatment or even a heal for a uncommon illness, or in as-nonetheless not known methods, “there’s no restrict on how irreplaceable” the frozen samples could be, mentioned Youthful, who explained GenVault and its staff as “the stewards” of supplies that could participate in a part in long term healthcare breakthroughs.

“A ton of our clients are performing uncommon sickness analysis,” DiMarino stated. “We can enable them triumph in their quest for a heal.”

The Race to Save Medical Research

Most Americans probably aren’t aware that the Department of Veterans Affairs (VA) healthcare system, along with the National Institutes of Health (NIH), is the best and biggest medical research powerhouse in the United States. Millions of veterans have benefited from VA research breakthroughs, including pioneering treatments for PTSD, Agent Orange, and prosthetics.

But it’s not just veterans who benefit. All Americans have profited from VA advances, such as the shingles vaccine, the implantable cardiac pacemaker, and the nicotine patch. The VA is on the frontlines of investigations on the risks of long COVID and studying why prostate cancer is so lethal for Black men. 

Quite distressingly, this peerless research system is now under threat. In a November hearing before the Senate Veterans Affairs Committee, the VA’s Under Secretary for Health, Shereef Elnahal, warned of catastrophic consequences should the Senate fail to follow the lead of the House and pass the VA Infrastructure Powers Exceptional Research (VIPER) Act. This legislation reverses a misguided Department of Justice (DOJ) ruling prohibiting VA employees from being paid by academic affiliates for joint research initiatives. Elnahal explained that without VIPER, “major clinical trials answering key questions across all of American medicine” will be at risk.

For decades, the VA has partnered with 90 percent of the nation’s academic medical centers like Boston University, Dartmouth, Yale, and many others. Through these partnerships, VA researchers who devoted up to 40 hours a week doing research, teaching students, and caring for veterans, could secure supplemental funds to investigate everything from the impacts of burn pits to potential cures for Alzheimer’s disease. Although the VA has its own stream of research funding, these academic partners are the conduits for researchers to receive money from non-VA sources like the Department of Defense (DOD), the Centers for Disease Control and Prevention (CDC), the NIH, as well as numerous private foundations like the Prostate Cancer Foundation. These partnerships are critical because federal law prohibits the VA from administering such funds. The funding also supplements VA salaries which are not competitive with those in the private sector. It enables the VA to attract and retain top scientists who devote their careers to the care of the nation’s veterans.

The DOJ ruling that caused the current predicament was issued in 2021. It reinterpreted federal law governing the payment of federal employees conducting research at the VA in partnership with the private sector medical centers. This applies to many of the VA’s key academic partners, such as Columbia, Baylor, Stanford, and Harvard, among many others. For 75 years, VA researchers were permitted – even encouraged – to receive part of their funding from private-sector academic medical centers. Suddenly, the DOJ decided those supplemental payments were illegal. A peculiar double standard was applied to partnerships with public universities like the University of California at San Francisco, which were deemed permissible.

Some researchers could lose a third of their income and face criminal prosecution. After attending a recent meeting of VA trauma researchers, a former VA official said that many clinicians are “heading for the hills.”

The VIPER Act will keep them from fleeing, and that’s why it passed the House with overwhelming bipartisan support.  But time is the enemy in the slower-moving Senate as the last days of this congress tick away.

Critical research hangs in the balance. As the VA’s 2024 budget request states unequivocally, the VA’s most important studies and initiatives involve “large multi-center clinical trials and epidemiological studies,” which depend on collaboration between private and public academic medical centers.

Consider, for example, the VA COVID-19 Observational Research Collaboratory (CORC) – a multi-site project that includes public and private universities. The collaborative has a database of 250,000 veterans infected with COVID-19. VA researchers recently released two studies detailing the severe consequences of long COVID.

Another area that could be impacted is prostate cancer research. In 2016, the Prostate Cancer Research Foundation gave the VA a $50 million grant hailed as a “unique public-private biomedical research partnership.” Why? Because the VA, over time, has millions of patients who have prostate cancer, and their data goes back decades. As the CEO and president of the foundation said at the time, the VA can help clarify “why, of 287 different kinds of cancer, even with identical care, prostate cancer is more aggressive and lethal in African-American men.” [MC4] Since 2016, VA has worked with researchers at various public and private universities to answer other critical questions about prostate cancer.

If not immediately reversed, the DOJ rule will also have catastrophic effects on brain research that depends on the VA’s Biorepository Brain Bank.  This partnership with Boston University has the world’s most extensive brain tissue collection. The seven-component VA-BU brain banks focus on ailments including PTSD, CTE, and ALS.  In 2018, Time magazine named its director, Ann McKee, one of the 50 most influential people in health care.  Her research on the brains of veterans and football players has helped establish a link between multiple concussions and the development of CTE. McKee and her colleagues may have to curtail their vital work if the DOJ action is not reversed. PTSD research being conducted by the VA’s National Centers for PTSD in collaboration with Boston University and Dartmouth will also be impacted. 

Again, these VA researchers’ knowledge and innovations don’t just help veterans. They’ve helped first responders suffering from PTSD following the 9/11 attacks and many other emergencies. To get to the president’s desk before the end of the year, Senators must attach VIPER to must-pass legislation such as the National Defense Authorization Act or the Omnibus Appropriations bill. If VIPER passes this year, the VA’s pivotal role in the American research enterprise will survive intact.  If not, a letter supporting VIPER addressed this week to the Senate by the American Psychological Association and the Association of American Medical Colleges and signed by more than 86 primary medical schools, veterans service organizations, and medical foundations and associations warned “thousands of research projects focused on improving veterans’ health led by VA scientists” will be disrupted.